<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82170">
  <stage>Registered</stage>
  <submitdate>24/07/2007</submitdate>
  <approvaldate>7/08/2007</approvaldate>
  <actrnumber>ACTRN12607000405415</actrnumber>
  <trial_identification>
    <studytitle>A Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes.</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo Controlled, Multicentre, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes. The ATLAS ACS TIMI 46 Study. 39039039-ACS-2001</scientifictitle>
    <utrn />
    <trialacronym>ATLAS ACS TIMI 46</trialacronym>
    <secondaryid>ClinicalTrials.gov: NCT00402597</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Coronary Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study is designed to evaluate the safety and efficacy of rivaroxaban in subjects with recent Acute Coronary Syndrome who are receiving background low-dose aspirin therapy (75 to 100 mg/day) without the intention to use a thienopyridine therapy or with thienopyridine therapy. 

There will be 2 stages. Stage 1 will be for dose escalation while Stage 2 will be for dose confirmation. 

In Stage 1 there will be 3 total daily dose levels of rivaroxaban or placebo. 5 mg (2.5 mg twice a day or 5 mg once daily), 10 mg (5 mg twice a day or 10 mg daily) and 20 mg (10 mg twice a day or 20 mg daily). Mode of administration is oral. Two more additional dose levels may be added depending on the safety and efficacy profile observed in the first 3 dose levels. Maximum daily dose will not exceed 30 mg. All randomised subjects are planned to receive 6 months of treatment.

In Stage 2, it is intended that a rivaroxaban once daily dose, twice daily dose or both will be selected for comparison to placebo. The dosage will be dependent upon the maximum tolerable dose for individual patient that was discovered during the dose escalation stage. Treatment will also be for 6 months.</interventions>
    <comparator>Placebo (sugar pill) - 1 placebo tablet twice daily for 6 months.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The number of patients with recent ACS taking rivaroxaban with background antiplatelet therapy who experience protocol-defined clinically significant bleeding (assessed by clinical assessment and optionally imaging procedures or laboratory tests as appropriate).
Timepoint: Day 1 to Day 210</outcome>
      <timepoint>The analysis of the outcome will be through to 6 months. The events will be collated as they occur over the 6 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The number of patients who experience death (all cause), MI, (or reMI), stroke, or ischemia requiring revascularization (assessed by clinical assessment and optionally imaging procedures or laboratory tests as appropriate).
Timepoint: Day 1 to Day 210</outcome>
      <timepoint>The analysis of the outcome will be through to 6 months. The events will be collated as they occur over the 6 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Have symptoms suggestive of ACS and a diagnosis of ST-elevation myocardial infarction or non-ST elevation myocardial infarction / unstable angina with at least 1 high risk feature. (ST is a section of the electrocardiograph wave.) </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Active bleeding or high risk of bleeding or intracranial haemorrhage.Need for continued anticoagulant therapy.Significantly impaired renal or hepatic function.Severe concomitant diseases such as cardiogenic shock, refractory ventricular arrhythmias, or any severe condition that would limit life expectancy to less than 6 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The packaging and dosage will be such that the different treatment groups will appear identical. An interactive voice response system (IVRS) will be used to accomplish a blind allocation.</concealment>
    <sequence>Computer generated random code.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>This is a double blind trial, meaning that the subjects receiving the treatment and all the researchers are blinded to the treatments.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>17/11/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>3490</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer Australia Limited</primarysponsorname>
    <primarysponsoraddress>875 Pacific  Highway
Pymble NSW 2073</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bayer Australia Limited</fundingname>
      <fundingaddress>875 Pacific  Highway
Pymble NSW 2073</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Bayer Australia Limited</sponsorname>
      <sponsoraddress>875 Pacific  Highway
Pymble NSW 2073</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to evaluate the safety of rivaroxaban in subjects with recent acute coronary syndrome and to assess the ability of rivaroxaban to reduce the rate of clinical events in those patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress>Perth WA</ethicaddress>
      <ethicapprovaldate>12/02/2007</ethicapprovaldate>
      <hrec>RA-07/002</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Concord Repatriation General Hospital</ethicname>
      <ethicaddress>NSW</ethicaddress>
      <ethicapprovaldate>6/02/2007</ethicapprovaldate>
      <hrec>CH62/6/2006-125</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Prince Charles Hospital</ethicname>
      <ethicaddress>QLD</ethicaddress>
      <ethicapprovaldate>10/01/2007</ethicapprovaldate>
      <hrec>EC2692</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Queen Elizabeth Hospital</ethicname>
      <ethicaddress>SA</ethicaddress>
      <ethicapprovaldate>22/01/2007</ethicapprovaldate>
      <hrec>2006162</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Cardiology Research Unit</ethicname>
      <ethicaddress>VIC</ethicaddress>
      <ethicapprovaldate>13/03/2007</ethicapprovaldate>
      <hrec>07/01</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress>VIC</ethicaddress>
      <ethicapprovaldate>19/02/2007</ethicapprovaldate>
      <hrec>04189</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress>VIC</ethicaddress>
      <ethicapprovaldate>27/02/2007</ethicapprovaldate>
      <hrec>E66/0607</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Fremantle Hospital</ethicname>
      <ethicaddress>WA</ethicaddress>
      <ethicapprovaldate>1/02/2007</ethicapprovaldate>
      <hrec>06/575</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wesley Research Institute</ethicname>
      <ethicaddress />
      <ethicapprovaldate>14/03/2007</ethicapprovaldate>
      <hrec>2007/01</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Phil Aylward</name>
      <address>1 Flinders Medical Centre
Flinders Drive
Bedford SA 5042</address>
      <phone>08 82042001</phone>
      <fax />
      <email>phil.alyward@fmc.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Phil Aylward</name>
      <address>Flinders Medical Centre
1 Flinders Drive
Bedford SA 5042</address>
      <phone>08 82042001</phone>
      <fax />
      <email>phil.alyward@fmc.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>